Dync1Li2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
[@dyncli]
Overview
This page provides comprehensive information about the subject's role in neurodegenerative diseases. The subject participates in various molecular pathways and cellular processes relevant to Alzheimer's disease, Parkinson's disease, and related conditions.
Dync1Li2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
[@dyncli]
Overview
This page provides comprehensive information about the subject's role in neurodegenerative diseases. The subject participates in various molecular pathways and cellular processes relevant to Alzheimer's disease, Parkinson's disease, and related conditions.
termediate chain family |
Structure
DYNC1LI2 (Dynein Cytoplasmic 1 Light Intermediate Chain 2) is a ~450 amino acid protein belonging to the dynein light intermediate chain family. The protein consists of an N-terminal cargo-binding domain and a C-terminal dynein heavy chain interaction domain [1](https://www.uniprot.org/uniprot/Q8IWV1). DYNC1LI2 shares structural similarity with DYNC1LI1 and can form both homodimers and heterodimers, allowing for functional diversification of the dynein complex [2](https://pubmed.ncbi.nlm.nih.gov/23430052/).
The protein contains a P-loop NTP-binding domain typical of the SIMIBI family of NTP-binding proteins, enabling ATP-dependent conformational changes required for dynein motor activity [3](https://www.ebi.ac.uk/interpro/entry/interpro/IPR027417).
Normal Function
The cytoplasmic dynein-1 complex is the major minus-end-directed microtubule motor in eukaryotic cells, responsible for retrograde transport from the cell periphery toward the cell body. DYNC1LI2 serves as a crucial adaptor subunit that:
Cargo Binding and Regulation: Links diverse cargoes to the dynein motor complex, including membranous organelles, protein complexes, and RNA granules [4](https://pubmed.ncbi.nlm.nih.gov/19793869/)
Neuronal Transport: Facilitates retrograde transport in neuronal axons, delivering signaling endosomes, synaptic vesicle precursors, and autophagosomes from synapses back to cell bodies for degradation or recycling [5](https://pubmed.ncbi.nlm.nih.gov/22495302/)
Dynein Complex Assembly: Participates in cytoplasmic dynein-1 complex assembly, stabilizing the motor complex and modulating its activity [6](https://pubmed.ncbi.nlm.nih.gov/23430052/)
Mitosis and Cell Division: Involved in mitotic spindle positioning and organelle transport during cell division
Role in Neurodegeneration
Dysregulation of axonal transport is a hallmark feature of many neurodegenerative diseases. DYNC1LI2 has been implicated in several disease mechanisms:
Alzheimer's Disease (AD)
Impaired dynein-mediated retrograde transport contributes to disrupted signaling between synapses and cell bodies in AD [7](https://pubmed.ncbi.nlm.nih.gov/23643691/)
[Amyloid-beta](/proteins/amyloid-beta) oligomers can directly impair dynein function, affecting the transport of [App](/entities/app-protein)-containing vesicles and contributing to axonal trafficking deficits
Reduced DYNC1LI2 expression may contribute to the accumulation of damaged organelles in distal axons
Parkinson's Disease (PD)
[Alpha-synuclein](/proteins/alpha-synuclein) aggregates can sequester dynein light chains, disrupting retrograde transport of neurotrophic factors [8](https://pubmed.ncbi.nlm.nih.gov/23797056/)
Impaired retrograde transport of signaling endosomes may contribute to dopaminergic neuron vulnerability in the substantia nigra
Amyotrophic Lateral Sclerosis (ALS)
Mutations in dynein complex components have been linked to ALS pathogenesis
Disrupted axonal transport of RNA granules and organelles contributes to synaptic dysfunction
[TDP-43](/mechanisms/tdp-43-proteinopathy) pathology may affect dynein-mediated transport mechanisms
Charcot-Marie-Tooth Disease (CMT)
Mutations affecting microtubule-based transport proteins, including dynein adaptors, can cause CMT neuropathy
DYNC1LI2 dysfunction may contribute to the distal axon degeneration characteristic of CMT
Therapeutic Implications
Targeting dynein-mediated transport represents a potential therapeutic strategy:
Microtubule-stabilizing agents can improve axonal transport in models of transport deficits
Dynein modulators that enhance motor activity without causing toxicity are under investigation
Gene therapy approaches to restore proper transport function are being explored
Key Publications
[Dynein light intermediate chains: versatile adaptors for cytoplasmic dynein (2013)](https://pubmed.ncbi.nlm.nih.gov/23430052/) - Cell Mol Life Sci
[Axonal transport deficits in neurodegenerative disease (2013)](https://pubmed.ncbi.nlm.nih.gov/22495302/) - Nat Neurosci
[Dynein dysfunction in amyloid-beta toxicity (2013)](https://pubmed.ncbi.nlm.nih.gov/23643691/) - J Neurosci
[Alpha-synuclein and dynein interplay in PD (2014)](https://pubmed.ncbi.nlm.nih.gov/23797056/) - Mov Disord
Background
The study of Dync1Li2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
External Links
[PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
[Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
[Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data